[Edaily Starin YUN GI BACK Reporter] The group aespa will kick off their new world tour with their first performance at Gocheok Sky Dome in Seoul. aespa (Photo: SM Entertainment) According to their agency, SM Entertainment, aespa will kick off their fourth world tour, “2026-27 aespa LIVE TOUR - SYNK: COMPLaeXITY,” at Seoul’s Gocheok Sky Dome on the 7th and 8th. This marks their first performance at Gocheok Sky Dome since their debut and serves as the starting point for a global tour that will visit 25 cities. This concert goes beyond simply showcasing new songs; it expands the narrative universe established in their second full-length album, “LEMONADE,” through the language of stage performance. Structured around the theme of “CRACK,” the show is divided into five chapters, each featuring distinct atmospheres and staging to weave a cohesive narrative. Various viewing options have been arranged. The first day’s performance will be screened via live viewing at 146 movie theaters across 11 regions worldwide, including South Korea, while the second day’s performance will be streamed live via Beyond LIVE and Weverse. Fans unable to attend in person can still experience the atmosphere of the venue through these various platforms. After wrapping up their Seoul concert, aespa will tour 25 regions, including North and South America and Europe, to meet with global fans. This tour is drawing attention not only for its significantly expanded scale but also for introducing new performance content that organically integrates music, the group’s universe, and stage direction. Expectations are high to see what milestone this concert—their first solo concert at Gocheok Dome and the starting point of their fourth world tour—will mark in aespa’s global journey.
E-Land World (BBB0) is set to issue up to 40 billion won in public corporate bonds. With investor sentiment toward BBB-rated corporate bonds currently subdued, all eyes are on whether the company can …
(Photo courtesy of MedPacto, Inc.)
MedPacto, Inc.(235980)is adding a medium-dose patient group to the Phase 2 clinical trial of “Vactosertib,” which it is developing as a treatment for osteosarcom…
Medical artificial intelligence (AI) company Coreline Soft Co., Ltd.(384470)announced on the 7th that it has secured a contract for a lung cancer screening project in Lostau, Germany, through Canon Me…